Basic Information

Gene symbol CTAG1B Synonyms CTAG, ESO1, CT6.1, CTAG1, LAGE-2, LAGE2B, NY-ESO-1 Type of gene protein-coding
Description cancer/testis antigen 1B

GTO ID GTC0413
Trial ID NCT03399448
Disease Multiple Myeloma | Synovial Sarcoma | Myxoid Liposarcoma
Altered gene NY-ESO-1
Therapeutic/Target gene Target gene
TherapyTCR-T cell
Treatment NY-ESO-1 TCR-T cells
HLAHLA-A2*02:01
PhasePhase1
Recruitment statusTerminated
TitlePhase 1 Trial of Autologous T Cells Engineered to Express NY-ESO-1 TCR and CRISPR Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T Cells)
Year2012
CountryUnited States
Company sponsorUniversity of Pennsylvania
Other ID(s)UPCC# 25416|IRB #826672
Vector information
Vectorlentivirus
Transgene/Inserted geneCTAG1B
Vector production methodThe T cell product was manufactured by electroporation of ribonucleoprotein complexes (RNP) comprising recombinant Cas9 loaded with equimolar mixtures of sgRNA for TRAC, TRBC and PDCD1 followed by lentiviral transduction of the transgenic TCR. All products were expanded to >1x1010 T cells by the time of harvest. The transgenic TCR could be detected by flow cytometric staining for Vβ8.1 or dextramer staining, ranging from 2 - 7% of T cells in the final product.

Clinical Result

Cohort1: MM
Administration route infusion
Dosage 0.6~7.1E8 cells
Donor type autologous
Pts 2
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 1/2(SD)
Adverse reactions none(grade 3 or higher)
References PMID: 32029687
Cohort2: SS and MRCL
Administration route infusion
Dosage 0.6~7.1E8 cells
Donor type autologous
Pts 1
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 1/1(SD)
Adverse reactions none(grade 3 or higher)
References PMID: 32029687

Relationship Graph

Overview of Knowledge Graph